Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Journal of Hematology & Oncology
|
April 17, 2020
An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination
Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, et al.
Drug Delivery
|
May 9, 2022
GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases
Rita Sala, Elisa Rioja-Blanco, Naroa Serna, et al.
Pharmaceutics
|
April 23, 2022
A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model
Elisa Rioja-Blanco, Alberto Gallardo, Irene Arroyo-Solera, et al.
Biomedicines
|
July 27, 2022
Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease
Esperanza Medina-Gutiérrez, María Virtudes Céspedes, Alberto Gallardo, et al.
Pharmacological Research
|
October 13, 2025
Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer
Luis M Carrasco-Díaz, Marc Otero-Mateo, Patricia Álamo, et al.
Acta Pharmaceutica Sinica. B
|
June 1, 2022
Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4<sup>+</sup> head and neck squamous cell carcinoma tumors
Elisa Rioja-Blanco, Irene Arroyo-Solera, Patricia Álamo, et al.
Materials Today. Bio
|
January 21, 2026
Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates
Ariana Rueda, Annabel Garcia-Leon, Lourdes A Arena, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 5, 2022
CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
Elisa Rioja-Blanco, Irene Arroyo-Solera, Patricia Álamo, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
PM534, a Novel Colchicine‑Site Tubulin Inhibitor with Broad‑Spectrum and Resistance‑Overcoming Antitumor Activity
Pablo Aviles, Marcelo Lima Ribeiro, Maria Jose Guillén, et al.
Plos One
|
June 20, 2018
CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis
María José Moreno, Alberto Gallardo, Silvana Novelli, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Journal of Hematology & Oncology
|
April 17, 2020
An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination
Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, et al.
Drug Delivery
|
May 9, 2022
GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases
Rita Sala, Elisa Rioja-Blanco, Naroa Serna, et al.
Pharmaceutics
|
April 23, 2022
A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model
Elisa Rioja-Blanco, Alberto Gallardo, Irene Arroyo-Solera, et al.
Biomedicines
|
July 27, 2022
Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease
Esperanza Medina-Gutiérrez, María Virtudes Céspedes, Alberto Gallardo, et al.
Pharmacological Research
|
October 13, 2025
Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer
Luis M Carrasco-Díaz, Marc Otero-Mateo, Patricia Álamo, et al.
Acta Pharmaceutica Sinica. B
|
June 1, 2022
Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4<sup>+</sup> head and neck squamous cell carcinoma tumors
Elisa Rioja-Blanco, Irene Arroyo-Solera, Patricia Álamo, et al.
Materials Today. Bio
|
January 21, 2026
Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates
Ariana Rueda, Annabel Garcia-Leon, Lourdes A Arena, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 5, 2022
CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
Elisa Rioja-Blanco, Irene Arroyo-Solera, Patricia Álamo, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
PM534, a Novel Colchicine‑Site Tubulin Inhibitor with Broad‑Spectrum and Resistance‑Overcoming Antitumor Activity
Pablo Aviles, Marcelo Lima Ribeiro, Maria Jose Guillén, et al.
Plos One
|
June 20, 2018
CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis
María José Moreno, Alberto Gallardo, Silvana Novelli, et al.
Page
of 6